Krystal Biotech (NASDAQ:KRYS) Research Coverage Started at Wolfe Research

Wolfe Research initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research report released on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the stock.

A number of other brokerages have also recently issued reports on KRYS. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Citigroup boosted their price target on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. The Goldman Sachs Group upped their price objective on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Bank of America raised their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $326.25.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $245.39 on Friday. The firm’s fifty day moving average price is $267.34 and its two-hundred day moving average price is $230.46. The stock has a market cap of $7.17 billion, a PE ratio of 35.82 and a beta of 0.49. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. As a group, sell-side analysts predict that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, Director Daniel Janney sold 37,895 shares of Krystal Biotech stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $266.88, for a total transaction of $10,113,417.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Dino A. Rossi sold 18,950 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $261.41, for a total value of $4,953,719.50. Following the completion of the sale, the director owned 78,691 shares in the company, valued at $20,570,614.31. This trade represents a 19.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 over the last 90 days. 13.70% of the stock is owned by corporate insiders.

Institutional Trading of Krystal Biotech

Institutional investors have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. increased its position in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Braidwell LP lifted its position in shares of Krystal Biotech by 81.6% in the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares during the period. Norges Bank acquired a new position in shares of Krystal Biotech in the 4th quarter worth approximately $70,159,000. William Blair Investment Management LLC boosted its stake in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after buying an additional 209,369 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.